Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1816 to 1830 of 8887 results

  1. Subcutaneous efgartigmod for treating generalised myasthenia gravis [TSID11835]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. High-dose aflibercept for treating wet age-related macular degeneration [TSID10590]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Semaglutide for treating type 2 diabetes and associated peripheral arterial disease [TSID11791]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Sacubitril valsartan for treating chronic heart failure with reduced ejection fraction in people under 18 years [TSID10350]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Macitentan for treating pulmonary arterial hypertension in people 1 month to 17 years [TSID11805]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia [TSID12043]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Linaclotide acetate for treating Chronic idiopathic constipation [TSID12005]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. IgPro20 for treating dermatomyositis [TSID12014]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Basal insulin icodec–semaglutide for treating type 2 diabetes inadequately controlled with daily basal insulin [TSID11940]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Olorofim for treating invasive fungal infections in people 16 years and over [TSID11983]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years [TSID12002]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Secukinumab biosimilar for treating plaque psoriasis [TSID11992]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Subcutaneous isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [TSID11969]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Respirasense

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  15. Canakinumab for untreated Schnitzler syndrome [ID4063]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation